- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Americans more likely than others to prefer generics, study finds
- Facing pharmacy trends for the remainder of the year
- State of the market: Are generic drugs approaching their peak?
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
WASHINGTON — The Generic Pharmaceutical Association has appointed a new executive who will help guide the organization's newly created research and education institute.
The organization announced Thursday the appointment of Ahaviah Glaser as VP policy and strategic alliances. Glaser previously was a member of AARP's government affairs team.
"Through GPhA and the newly created Affordable Medicines Research Institute, Havi will help educate both the public at large and policy makers around the world about the safety and efficacy of generic medicines, as well as the extraordinary healthcare savings that generics provide," GPhA president and CEO Ralph Neas said.
"In a time when budget challenges and healthcare costs are colliding as never before, not only for governments but for families, Havi's job will be to help shepherd research, education and outreach efforts to ensure that all Americans fully understand that generic pharmaceuticals reduce healthcare costs while maintaining the high-quality standard of care that they rightly expect," Neas added.